Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7753308 | 1.00 | KIF11 (0.68) | KIF11DNMT1 | |
| SCHEMBL15978681 | 1.00 | KIF11 (0.68) | KIF11DNMT1 | |
| S-Trityl-L-Cysteine SCHEMBL768202 | 0.88 | KIF11 (0.85) | KIF11DNMT1 | |
| S-Trityl-L-Cysteine SCHEMBL768203 | 0.88 | KIF11 (0.85) | KIF11DNMT1 | |
| S-Trityl-L-Cysteine SCHEMBL6891349 | 0.88 | KIF11 (0.85) | KIF11DNMT1 | |
| SCHEMBL14432855 | 0.87 | KIF11 (0.83) | KIF11DNMT1 | |
| SCHEMBL15848662 | 0.87 | KIF11 (0.64) | KIF11DNMT1 | |
| SCHEMBL14432853 | 0.87 | KIF11 (0.83) | KIF11DNMT1 | |
| SCHEMBL27988674 | 0.87 | KIF11 (0.65) | KIF11DNMT1 | |
| SCHEMBL27988671 | 0.87 | KIF11 (0.65) | KIF11DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116606233-A | Preparation method of S-trityl-L-cysteamine | 康化（上海）新药研发有限公司 | 2023-08-18 | — | — | CN | claimed |
| US-12565506-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | Clarity Pharmaceuticals Ltd (AU) | 2026-03-03 | — | — | US | disclosed |
| US-12503498-B2 | Fc containing polypeptides with altered glycosylation and reduced effector function | GENZYME CORPORATION (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4640239-A2 | SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES | Genzyme Corporation (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4015535-B1 | SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES | GENZYME CORP (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-119552215-A | Tumor targeting polypeptides, conjugates comprising same, compositions and uses | 苏州星洲生物科技有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20250066497-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING | GENZYME CORPORATION | 2025-02-27 | — | — | US | disclosed |
| WO-2025006830-A2 | COMPOUNDS FOR THE TREATMENT OF RETINITIS PIGMENTOSA AND METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF MISSISSIPPI (US) | 2025-01-02 | — | — | WO | disclosed |
| CN-113975406-B | Glycoengineered antibody drug conjugates | 建新公司 | 2024-11-22 | — | — | CN | disclosed |
| US-12110338-B2 | Site-specific antibody-drug conjugation through glycoengineering | GENZYME CORPORATION (US) | 2024-10-08 | — | — | US | disclosed |
| US-20040029814-A1 | Dipeptide nitriles | ALTMANN EVA (CH) | 2004-02-12 | — | — | US | disclosed |
| US-6353017-B1 | INHIBITORS OF CATHESPINS USING DIPEPTIDE NITRILES AS ANTIINFLAMMATORY AGENTS AND ANTIARTHRITIC AGENTS | NOVARTIS AG (CH) | 2002-03-05 | — | — | US | disclosed |
| US-6313123-B1 | FOR THERAPY OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, SEPSIS, AIDS, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, CROHN'S DISEASE AND DEGENERATIVE CARTILAGE LOSS | AMERICAN CYANAMID COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-1149074-A1 | ACETYLENIC SULFONAMIDE THIOL TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-0633267-B1 | Process for the preparation of alpha-amino acid amide for use in peptide synthesis | SOLVAY (BE) | 2001-09-26 | — | — | EP | disclosed |
| EP-1068176-A1 | CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS | Jomaa, Hassan (DE) | 2001-01-17 | — | — | EP | disclosed |
| WO-2000044716-A1 | ACETYLENIC SULFONAMIDE THIOL TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000027803-A1 | CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS | JOMAA, HASSAN (DE) | 2000-05-18 | — | — | WO | disclosed |
| US-5506362-A | Process for the preparation of an α-amino acid amide | SOLVAY (SOCIETE ANONYME) (BE) | 1996-04-09 | — | — | US | disclosed |
| EP-0633267-A1 | Process for the preparation of an alpha-amino acid amide for use in peptide synthesis | SOLVAY (Société Anonyme) (BE) | 1995-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565506-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | CA12, CLTC, CA13 | KIF11 3449/4885DNMT1 4238/4885 |
| US-12110338-B2 | Site-specific antibody-drug conjugation through glycoengineering | CD2BP2, SIGLEC7, B3GAT3 | KIF11 2605/4885DNMT1 1142/4885 |
| US-20250066497-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING | SIGLEC9, SIGLEC7, STT3B | KIF11 2232/4885DNMT1 551/4885 |
| US-12503498-B2 | Fc containing polypeptides with altered glycosylation and reduced effector function | FCGR3B, FCGRT, FCGR2A | KIF11 4467/4885DNMT1 2293/4885 |
| US-20040029814-A1 | Dipeptide nitriles | NOS1, CTSL, CTSS | KIF11 4552/4885DNMT1 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.